Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Total raised

$8M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025